CSPG4 and melanoma: Given these encouraging preclinical reports on CSPG4 as an immunotherapeutic target, we set out to further characterize the two previously identified HLA-C*07:01-restricted melanoma reactive T-cell clones 11C/73 and 2C/165 directed against the TAA CSPG4.